MedTrace Logo

Effect of Adding Magnesium Sulphate in Pericapsular Nerve Group Block

NCT06180031 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2023-12-22

No results posted yet for this study

Summary

Our aim will be to compare the analgesic efficacy and safety of magnesium sulphate as an adjuvant to bupivacaine in pericapsular nerve group block in Hip joint surgeries.

* Our primary outcome of the study: total amount of postoperative morphine consumption in the first 24h postoperative.
* Our secondary outcome of the study: mean arterial blood pressure, heart rate, respiratory rate, adverse effects, block related complication, sedation score (by Ramsay sedation scale) and pain score (by Visual Analog Scale)

Conditions

  • Hip Fractures

Interventions

DRUG

Pericapsular nerve group block using bupivicaine and magnesium sulphate

This technique involves the deposition of the local anesthetic in the fascial plane between the psoas muscle and the superior pubic ramus

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Alaa M Attia, Professor · Assiut University

  • Fatma A Abd Diab, Associate Professor · South Egypt's cancer institute, Assiut University

  • Moaz Tohamy, Lecturer · South Egypt's cancer institute, Assiut University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2025-01-01
Completion
2025-03-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06180031 on ClinicalTrials.gov